The E2F family, classically known for a central role in cell cycle, has a number of emerging roles 35 in cancer including angiogenesis, metabolic reprogramming, metastasis and DNA repair. E2F1 36 specifically has been shown to be a critical mediator of DNA repair; however, little is known about 37 DNA repair and other E2F family members. Here we present an integrative bioinformatic and 38 high throughput drug screening study to define the role of E2F2 in maintaining genomic integrity 39 in breast cancer. We utilized in vitro E2F2 ChIP-chip and over expression data to identify 40 transcriptional targets of E2F2. This data was integrated with gene expression from E2F2 41 knockout tumors in an MMTV-Neu background. Finally, this data was compared to human 42 datasets to identify conserved roles of E2F2 in human breast cancer through the TCGA breast 43 cancer, Cancer Cell Line Encyclopedia, and CancerRx datasets. Here we have computationally 44 predicted that E2F2 transcriptionally regulates key mediators of DNA repair. Our gene expression 45 data supports this hypothesis and low E2F2 activity is associated with a highly unstable tumor. In 46 human breast cancer E2F2, status was also correlated with a patient's response to PARP inhibition 47 therapy. Taken together this manuscript defines a novel role of E2F2 in cancer progression beyond 48 cell cycle and could be therapeutically relevant. 49 50 Author Summary 51 The E2F family of proteins have been known to regulate cell cycle and have recently been shown 52
Introduction 65
Breast cancer remains the leading cause of cancer related deaths in women. This is largely 66 due to two factors, metastasis and the heterogeneity of breast cancer. While metastasis to distal 67 sites is responsible for mortality, the difficulty of treating a heterogeneous disease is one of the 68 primary factors allowing that progression to occur. The heterogeneity of breast cancer is evident 69 in several facets, including histological subtypes, progression and response to treatment. 70 Underlying this diversity are the unique genomic alterations, methylation patterns and the resulting 71 gene expression differences that are recognized in the PAM50 classification system (1, 2) . Each 72 of the subtypes present (Luminal A/B, Basal, Claudin Low, HER2+ve and normal like) have a 73 unique transcriptomic profile, resulting in the dysregulation in key proteins in breast cancer, 74 including the alteration of the E2F family of transcription factors (3) (4) (5) (6) (7) . 75 The E2F family of transcription factors is composed of nine unique family members (E2F1, 76 E2F2, E2F3a, E2F3b, E2F4, E2F5, E2F6, E2F7, and E2F8) (8-10). These family members bind a 77 conserved motif with gene specificity contributed by cofactors (11) (12) (13) . As a result, the E2Fs have 78 been shown to directly regulate many downstream genes. Classically they have been divided into 79 family members that activate transcription (E2F1, E2F2, and E2F3a) and repressors of 80 transcription (E2F3b, E2F4, E2F5, E2F6, E2F7, and E2F8). These definitions have recently 81 become less clear, with each family member functioning in both activating and repressing roles 82 depending on the tissue and developmental context (11, 14) . 83 The role of the E2F family has widely been described in cell cycle where the members 84 regulate the G1/S checkpoint in response to Cyclin D levels (15, 16) . However, beyond the G1/S 85 checkpoint de-regulation E2Fs have a number of emerging roles in cancer (17). This includes 86 roles in other aspects of cancer progression including angiogenesis (18), metabolic reprograming 87 (19), and apoptosis (20, 21) . Indeed, numerous accounts detail the role of the activators in 88 metastasis of human breast cancer as well as mouse models of the disease (3, 4, 6, (22) (23) (24) . 89 An additional emerging role for the E2Fs has been in the regulation of genomic stability.
90
Specifically, the role of E2F1 has been well defined with both transcriptional and non-91 transcriptional roles in DNA repair (25) . In response to DNA damage, E2F1 undergoes post 92 translational phosphorylation by ATM (26), leading to protein stabilization and increased 93 expression of repair proteins. In addition to the transcriptional role in DNA repair, E2F1 is 94 physically recruited to sites of damage. During cases of double stranded breaks (27) or UV damage 95 (28) it was observed that E2F1 formed foci with other damage induced proteins at the site of DNA 96 damage. It has been shown the E2F1 is required for the efficient recruitment of other repair proteins 97 including XPA/XPC (28) and NBS1 (29). It has also been shown that E2F2 is transcriptionally 98 upregulated in response to DNA damage and has been shown to complex with Rad51 and sites of 99 DNA damage in neuronal cells (30).
100
The amplification of the centrosome within a cell leads to defects in cellular segregation 101 and DNA replication, which in turn leads to the single nucleotide variants, copy number 102 alterations, and translocations characteristics. Importantly, activator E2Fs have been shown to be 103 associated with centrosome amplification (31). It is through this amplification of the centrosome 104 that it is believed E2Fs contribute to the DNA instability associated with their misregulation.
105
However, the mechanism and specific E2Fs involved in this process remain unclear.
106
Together, there is an emerging role for the activator E2Fs role in maintaining genomic 107 integrity, but only the role of E2F1 has been well defined. Here we present a key role for E2F2 in 108 maintaining genomic integrity. Through the use of cell lines, mouse models, and human samples, 109 we have identified that low E2F2 activity level is associated with tumors containing high levels of 110 genomic instability. Furthermore, the levels of E2F2 have direct impact on therapeutic response 111 in clinical data. Indeed, tumors with high E2F2 activity have an increased sensitivity to cell cycle 112 targeted chemotherapy as well as targeted PARP inhibitors.
114

Results
115
Based on the published literature for E2Fs in non-cell cycle roles, we hypothesized that 116 E2F2 had key activities other than the traditional role in cell cycle. To test this hypothesis in large 117 transcriptomic datasets, we used principle components analysis on gene expression data from cells 118 infected with adenoviral delivered GFP compared with adenoviral delivered E2F2 ( Figure 1A) .
119
This analysis revealed a consistent gene expression profile associated with over expression of 120 E2F2 ( Figure 1B ). We used Significance Analysis of Microarrays (SAM) (32) analysis to identify 121 consistently overexpressed genes with the infection of Ad-E2F2 relative to GFP. E2F2 induction 122 allowed for the identification of overrepresented gene ontology groups through the use of 123 PANTHER analysis ( Figure 1C ). As expected, this uncovered over-representation of cell cycle 124 proteins. Interestingly we also identified a number of repair associated gene ontology groups, 125 including double-stranded break repair and non-recombinational repair. 126 To identify genes and pathways directly regulated by E2F2, we utilized publicly available 127 E2F2 ChIP-Chip data ( Figure 1D ) (33). This revealed numerous genes bound by E2F2 across the 128 genome. When target genes were analyzed with PANTHER and GATHER, the ontologies were 129 consistent with the E2F2 overexpression data. Indeed, cell cycle and DNA damage repair gene Joining, Base Excision repair, and nucleotide excision repair. This analysis illustrated that E2F2 138 regulates key proteins in each repair pathway ( Figure 1G ). 139 To determine if there is a role for E2F2 in DNA repair processes in the in vivo setting, we 140 utilized publicly available E2F2 knockout transcriptome data within the MMTV-Neu mouse model 141 mammary tumors (3, 34) . Unsupervised clustering identified a consistent transcriptional profile 142 with E2F2 loss (Figure 2A ). This revealed five major clusters, three primarily composed of 143 MMTV-Neu E2F2 knockout samples and two clustered primary populated with MMTV-Neu E2F 144 wildtype samples. This demonstrated a unique gene expression profile associated with the loss of 145 E2F2, which was unique relative to the MMTV-Neu E2F wildtype background. To explore the 146 enriched cellular processes in this data, we used Gene Set Enrichment Analysis (GSEA) comparing 147 MMTV-Neu tumors with and without E2F2. This revealed, similar to the in vitro data, that E2F2 148 null samples were enriched for both the instability gene set ( Figure 2B ) and the repair gene set 149 ( Figure 2C ). We do not believe this to be in conflict with the in vitro data with an upregulated 150 gene expression signature for repair not necessarily correlating with an increase in the repair 151 process. 152 To test whether misregulation of E2F2 associated repair and instability functions were 153 associated with a more unstable tumor, we predicted gene copy number alterations across the 154 genome. We utilized the Analysis of CNAs by Expression data (ACE) algorithm (35) to predict 155 copy number profiles of control FVB wildtype mammary glands ( Figure 3A ), MMTV-Neu E2F2 156 wildtype mammary tumors ( Figure 3B ), and MMTV-Neu E2F2 knockout mammary tumors 157 ( Figure 3C ). Examining a portion of chromosome 4 as a case study, we observed an increased 158 number of significant (p<.05) amplification and deletion events in the MMTV-Neu E2F2 knockout 159 samples relative to both wild FVB mammary controls and MMTV-Neu E2F2 wildtype tumors.
160
Expanding to the entire genome, this was a consistent across genotypes with the E2F2 knockout 161 samples being the most unstable ( Figure 3D ). Interestingly, when this was compared to the E2F1 162 knockout samples we also saw the E2F2 null samples to be increasingly unstable indicating a 163 specific role of E2F2 in genomic stability ( Figure S1 ).
164
While we have identified a potential role for E2F2 associated instability in mouse tumors, 165 this role has not previously been examined in human breast cancer. To address a potential role for 166 E2F2 in breast cancer, an E2F2 activity signature was used to divide the TCGA breast cohort into 167 low / high E2F2 activity groups. As predicted from the mouse mammary tumor data, human breast 168 cancer with low E2F2 activity contained significantly more copy number variants than those with 169 high E2F2 activity (p<.05) ( Figure 4A ). Furthermore, tumors with low predicted E2F2 activity 170 were observed to have enrichment for genomic instability in gene set enrichment analysis.
171
Specifically, there was a significant enrichment of genes involved with the response to UV induced 172 damage ( Figure 4B ).
173
In order to determine if E2F2 preferentially regulated a specific repair pathway, we utilized 174 single sample gene set enrichment analysis (ssGSEA) (36). The resulting scores were low/high 175 normalized to return an activity score between 0 and 1 for the four major repair pathways. Low 176 E2F2 activity resulted in significantly lower activity in each repair pathway including: Base 177 Excision Repair, Nucleotide Excision Repair, Homologous End Joining, and Non-Homologous 178 End joining ( Figure S2 ). Unsupervised hierarchical clustering of this data revealed that regardless 179 of the pathway, low E2F2 activity was associated with low ssGSEA pathway scores ( Figure 4C ).
180
Alterations in DNA repair pathways are manifested in response to therapy. Accordingly, 181 we sought to test whether E2F2 levels impacted therapeutic response using the CancerRx dataset.
182
After predicting the E2F2 activity level across all breast cancer datasets we identified differentially 183 lethal compounds between E2F2 low cell lines and E2F2 high cell lines (Table S2 ). This revealed 184 a number of interesting candidate compounds. For example. tumors with low E2F2 activity 185 responded poorly to cell cycle inhibiting compounds such as Cisplatin. However, they responded 186 well to PIK3 targeted therapy such as PI-103. In addition, we observed that tumors with high 187 E2F2 activity were sensitive to cell cycle compounds and resistant to other forms of therapy.
188
With a role for E2F2 in repair, we examined response to repair targeted therapy, including 189 PARP inhibitors. Surprisingly we identified that high E2F2 activity was associated with a 190 significantly higher response to common PARP inhibitors including Talazoparib ( Figure 5A Here we describe a role of E2F2 in repair and maintenance of genome integrity in both 202 MMTV-Neu mouse model mammary tumors as well as in human breast cancer patients. We have 203 identified this role using a combination of in silico, in vitro and in vivo datasets. Specifically, we 204 observed that E2F2 controls key members of many different repair pathways including HEJ, 205 NHEJ, BER, and NER. This involvement is associated with a genomically unstable tumors with 206 the loss of E2F2 activity in both the mouse model and the human disease.
207
Furthermore, this finding has direct clinical application. We have identified E2F2 activity 208 as a biomarker for response to cell cycle inhibition therapy. E2F2 activity, as determined by a 209 gene expression signature, correlates with PARP inhibition therapy. Interestingly, although 210 tumors with lowly active E2F2 are significantly more unstable than E2F2 tumors they are resistant 211 to PARP inhibitor therapy. We have identified that this effect is independent of BRCA1/2 status 212 and is correlated with E2F2 levels. This indicates that E2F2 has a role in PARP response and loss 213 of E2F2 may phenocopy or directly trigger other known causes of PARP inhibitor resistance. together, this data shows the key role that the E2Fs play in cancer progression and heterogeneity.
222
As central drivers of repair and due to the impact they have on the ability of a tumor to respond to 223 key therapies, there must be more research to understand the clinical application of E2F status and 224 the way that it should shape patient care.
225
Materials and Methods
226
Datasets Used
227
For the E2F2 overexpression data, Affymetrix cDNA microarray profiled gene expression data 228 was downloaded from previously published data (40). For E2F2 binding analysis we utilized 229 ChIP-Chip for data for E2F2 T lymphocytes isolated from 4-week-old C57B16:129SV mice (33).
230
For the E2F2 knockout data in the MMTV-Neu background we utilized the dataset GSE42533.
231
For the human patient analysis, we utilized the TCGA breast cancer cohort (41).
233
Overrepresentation analysis 234 All overrepresentation analysis experiments were performed through the use of GATHER (42) 235 and PANTHER bioinformatic analysis to identify overrepresented gene ontology groups.
236
Significant groups were noted filtered by a p value of less than .05 and a Bayes factor greater than E2F2 activity was assayed using a gene expression signature as previously described (37, 45, 46) .
253
Briefly this method identifies differentially expressed genes between Ad-GFP and Ad-E2F2 254 infected cell lines and uses binary regression analysis to compare unknown samples and known 255 controls from each group to get a score between 0 (low E2F2 activity) and 1 (high E2F2 activity). Breast cancer gene expression data was downloaded from the cancer cell line encyclopedia (47).
259
From this data E2F2 activity was predicted as described above. For drug sensitivity data, we 260 downloaded the small molecule sensitivity dataset from CancerRx.org. Breast cancer cell lines 261 were divided into high and low E2F2 activity groups and significantly different compounds 262 between the two groups were identified by significantly different IC50's as identified by a 263 student's T-test. The TCGA cohort reveals that low E2F2 activity is associated with higher number of genes with Rennhack - Figure S3 A B C
